๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Antibody response to inactivated polio vaccine (E-IPV) in children born to HIV positive mothers

โœ Scribed by M. Barbi; M. Bardare; C. Luraschi; G. Zehender; M. Clerici Schoeller; G. Ferraris


Publisher
Springer
Year
1992
Tongue
English
Weight
464 KB
Volume
8
Category
Article
ISSN
0393-2990

No coin nor oath required. For personal study only.

โœฆ Synopsis


In order to evaluate the response to immunization of HIV-infected children we studied the humoral response to an enhanced potency inactivated poliovaccine (E-IPV) of 43 children born of H1V seropositive mothers. All these subjects have been followed for 32 (15-48) months in order to ascertain their infection status.

After a course of 2 doses of E-IPV, 88% of children had neutralizing antibody (n.a.) titers > 1:4 to the 3 poliovirus serotypes and 100% to at least 2 polio strains. No statistically significant differences both as rates of n.a. positive subjects and as antibody levels were found between H1V infected children and those who lost HIV antibodies. The poorest response was observed in subjects with full-blown immunodeficiency (CD4 < 1000/mm 3, reduced response to PWM).

Sixteen children also received a booster dose of vaccine one year after the completion of the primary cycle. Infected and non-infected subjects responded to the same extent with high levels of n.a. to this immunization. Interestingly, the recall dose was also able to induce high n.a. titers in those HIV infected children who showed significant decreases of n.a. titers in the months following the end of the primary cycle.


๐Ÿ“œ SIMILAR VOLUMES


Long-term response to hepatitis B vaccin
โœ Li-Min Huang; Bor-Luen Chiang; Chin-Yun Lee; Ping-Ing Lee; Wei-Kuang Chi; Mei-Hw ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 66 KB ๐Ÿ‘ 2 views

Hepatitis B (HB) vaccine provides an uncertain duration of protection and the optimal timing of booster vaccine remains unclear. This study examined the immune response at 10 years of 118 children who had developed protective anti-HB surface (anti-HBs) levels after a primary series of HB immunizatio